A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)

被引：0
|
作者：
Zhang, L. [1 ]
Fang, W. F. [1 ]
Zhao, S. [1 ]
Yu, Y. [2 ]
Yong, T. X. [3 ]
Dong, X. [4 ]
Zhuang, W. [5 ]
Hu, Y. [6 ]
Luo, F. [7 ]
Wang, Q. [8 ]
Chu, Q. [9 ]
Fu, Z. [10 ]
Yao, Y. [11 ]
Ma, X. [12 ]
Ding, C. [13 ]
Hao, J. [14 ]
Yang, X. [14 ]
Wan, X. [14 ]
Li, M. [14 ]
Yang, Y. [14 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[3] Shandong Canc Hosp & Inst, Dept Resp Med, Jinan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol, Wuhan, Peoples R China
[5] Fujian Prov Canc Hosp, Dept Resp Med, Fuzhou, Peoples R China
[6] Hubei Canc Hosp, Dept Oncol, Wuhan, Peoples R China
[7] Sichuan Univ, West China Hosp, West China Sch Med, Lung Canc Ctr, Chengdu, Peoples R China
[8] Jiangsu Prov Hosp Tradit Chinese Med TCM, Dept Resp Med, Nanjing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[10] Wuhan Univ, Renmin Hosp, Hubei Gen Hosp, Canc Ctr, Wuhan, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China
[12] Qingdao Univ, Affiliated Qingdao Cent Hosp, Canc Ctr, Qingdao, Peoples R China
[13] Fourth Hosp Hebei Med Univ North Gate, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China
[14] CSPC Pharmaceut Grp Co Ltd, Clin Div, Shijiazhuang, Hebei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614MO
引用
收藏
页码：S1624 / S1625
页数：3
相关论文
共 50 条
  • [41] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
    Goldman, Jonathan W.
    Horinouchi, Hidehito
    Cho, Byoung Chul
    Tomasini, Pascale
    Dunbar, Martin
    Hoffman, David
    Parikh, Apurvasena
    Blot, Vincent
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases
    Hiroyasu Kaneda
    Kenji Sawa
    Haruko Daga
    Asuka Okada
    Yuki Nakatani
    Shinji Atagi
    Kyoichi Okishio
    Yoko Tani
    Yoshiya Matsumoto
    Koichi Ogawa
    Kenji Nakahama
    Motohiro Izumi
    Shigeki Mitsuoka
    Tomoya Kawaguchi
    Investigational New Drugs, 2021, 39 : 1598 - 1603
  • [43] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [44] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [45] Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
    Eide, Inger Johanne Zwicky
    Grut, Harald
    Helland, Aslaug
    Ekman, Simon
    Sorensen, Jens Benn
    Hansen, Karin Holmskov
    Gronberg, Bjorn Henning
    Cicenas, Saulius
    Koivunen, Jussi Pekka
    Mellemgaard, Anders
    Brustugun, Odd Terje
    ACTA ONCOLOGICA, 2021, 60 (12) : 1565 - 1571
  • [46] Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer
    Wang, Yue
    Nan, Juan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 27 - 29
  • [47] Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
    Yang, J. C.
    Reckamp, K.
    Kim, Y.
    Novello, S.
    Smit, E.
    Lee, J.
    Su, W.
    Akerley, W.
    Blakely, C.
    Bazhenova, L.
    Chiari, R.
    Hsia, T.
    Golsorkhi, T.
    Despain, D.
    Shih, D.
    Rolfe, L.
    Popat, S.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2397 - S2397
  • [48] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [49] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [50] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    BMC PULMONARY MEDICINE, 2022, 22 (01)
12345